Reassessing Twenty Years of Vaccine Development Against Tuberculosis
Tuberculosis (TB) remains the prime bacterial infection worldwide with 10.4 million infections and a death toll of 1.7 million people in 2016 according to WHO statistics. Tuberculosis is caused by members of the Mycobacterium tuberculosis complex, facultative intracellular bacteria able to thrive wi...
Format: | eBook |
---|---|
Language: | English |
Published: |
Frontiers Media SA
2018
|
Series: | Frontiers Research Topics
|
Subjects: | |
Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
Similar Items
-
Editorial: Reassessing Twenty Years of Vaccine Development against Tuberculosis
by: Ulrich E. Schaible, et al.
Published: (2018-02-01) -
Vaccination against M. tuberculosis – what next after BCG?
by: Marek Fol, et al.
Published: (2011-01-01) -
Co-Administration of Anticancer Candidate MK-2206 Enhances the Efficacy of BCG Vaccine Against Mycobacterium tuberculosis in Mice and Guinea Pigs
by: Rania Bouzeyen, et al.
Published: (2021-05-01) -
Advances in the characterization of a proteol iposome derived from Mycobacterium bovis BCG as vaccine candidate against tuberculosis
by: Nadine Alvarez-Cabrera, et al.
Published: (2014-12-01) -
Vaccine research and development: tuberculosis as a global health threat
by: Mohammed Maikudi Usman, et al.
Published: (2017-08-01)